LONDON - Haleon PLC (LSE/NYSE: HLN), a global leader in consumer health, has announced board changes following a shift in shareholding by Pfizer Inc. (NYSE:PFE) The company confirmed that David Denton has stepped down from his role as a Non-Executive Director on the board after Pfizer's stake in Haleon fell below 20%. This move, effective from Monday, is in accordance with the terms outlined in the Pfizer Relationship Agreement with Haleon.
In a subsequent appointment, Bláthnaid Bergin will join the Haleon board as an independent Non-Executive Director starting 24 February 2025. Bergin's extensive background in financial leadership and strategic planning in consumer-facing businesses is expected to contribute significantly to Haleon's board. Currently serving as the Chief Financial Officer of J Sainsbury plc (OTC:JSAIY), Bergin has been instrumental in shaping the company's financial strategy and enhancing operational efficiency. Her previous experience includes senior finance roles at Aviva (LON:AV), RSA, and GE across various international markets and a tenure as Non-Executive Director and Chair of the Audit Committee at Artemis Alpha Investment Trust.
Sir Dave Lewis (JO:LEWJ), Chair of Haleon, expressed gratitude to Denton for his contributions and welcomed Bergin, emphasizing her proven track record in financial leadership within the consumer sector. Haleon, known for brands such as Advil, Sensodyne, and Centrum, aims to leverage Bergin's expertise to bolster its position in the consumer health market.
The company has confirmed that there are no additional details to disclose under the UK Listing Rules pertaining to the appointment. This board change comes as part of Haleon's ongoing commitment to maintaining strong governance and strategic oversight. The information regarding these board changes is based on a press release statement from Haleon.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.